Get Your Personalized Supplement StackSupplement Stack Quiz

Liposomal Urolithin A

Also known as: Urolithin A, UA, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one

Overview

Urolithin A (UA) is a bioactive metabolite derived from ellagic acid, a compound found in foods like pomegranates, berries, and nuts. Unlike ellagic acid, UA is not directly ingested but is produced in the gut by specific microbiota. Liposomal Urolithin A refers to UA encapsulated within liposomes, a delivery system designed to enhance its absorption and systemic availability in the body. UA is primarily recognized for its potential geroprotective properties, particularly its ability to improve mitochondrial function and promote autophagy, a crucial cellular cleanup process. Research indicates its potential benefits in areas such as muscle health, metabolic regulation, neuroprotection, and inflammation reduction. While human clinical trials have demonstrated its safety and efficacy in certain contexts, ongoing research aims to further elucidate its long-term effects and broader physiological impacts.

Benefits

Urolithin A offers several evidence-based benefits, primarily related to cellular health and aging. It exhibits dose-dependent anti-inflammatory effects, observed in human trials at doses ranging from 10 to 1000 mg/day over periods of 28 days to 4 months. UA also upregulates mitochondrial genes and markers of autophagy and fatty acid oxidation, indicating improved mitochondrial health. In healthy individuals, it has been shown to increase muscle strength and endurance, though without significant effects on anthropometric measures. For pre-diabetic individuals, UA can improve insulin sensitivity and glucose metabolism by enhancing mitochondrial biogenesis in skeletal muscle. Preclinical studies in animal models of Alzheimer's disease suggest neuroprotective effects, including reduced amyloid-beta deposition, decreased neuroinflammation, and improved cognitive performance. Secondary benefits include modulation of gut microbiota, suppression of pro-inflammatory cytokines, promotion of brown adipose tissue activation, and enhanced lysosomal function. These benefits are particularly relevant for healthy aging adults, pre-diabetic individuals, and potentially those at risk for neurodegenerative conditions. While muscle strength improvements are statistically significant, their clinical magnitude varies. Anti-inflammatory effects are consistent and dose-dependent. Cognitive benefits are promising but require human confirmation.

How it works

Urolithin A primarily exerts its effects by activating mitophagy, a process that selectively removes dysfunctional mitochondria, thereby improving overall mitochondrial quality and function. It modulates key signaling pathways, including SIRT1/mTOR, which are central to aging and metabolic regulation. Its anti-inflammatory actions are mediated through the inhibition of NF-κB and MAPK pathways, leading to a reduction in the production of pro-inflammatory cytokines. Furthermore, UA enhances lysosomal acidification and function, which improves cellular clearance mechanisms crucial for cellular health and neuroprotection. The liposomal delivery system enhances UA's absorption and bioavailability by protecting it from degradation in the digestive tract and facilitating its uptake into cells.

Side effects

Urolithin A is generally well-tolerated, with clinical trials reporting only mild to moderate adverse events that were not considered serious or directly related to the supplement. No serious adverse effects or contraindications have been consistently documented in human studies to date. While comprehensive studies on drug interactions are limited, UA's status as a natural metabolite suggests minimal interaction potential. Specific populations, including the elderly and individuals with pre-diabetes, have been included in trials without significant safety concerns. However, as with any supplement, individuals with pre-existing medical conditions or those taking prescription medications should consult a healthcare professional before starting supplementation. Long-term safety data beyond four months of continuous use are still emerging, and pregnant or breastfeeding women should avoid use due to insufficient research.

Dosage

Effective dosages of Urolithin A in human clinical trials typically range from 10 mg to 1000 mg per day, with many studies utilizing doses between 250 mg and 500 mg daily. The duration of supplementation in these trials has varied from 28 days to 4 months. While liposomal formulations are designed to improve bioavailability, potentially allowing for lower effective doses, direct comparative studies on dosing between liposomal and non-liposomal forms are limited. There is currently no established maximum safe dose, but doses up to 1000 mg/day have been administered without significant adverse effects. For optimal absorption, it is often recommended to take Urolithin A with a meal, though specific timing recommendations can vary by product. Individuals should follow the dosage instructions provided by the manufacturer or consult with a healthcare professional to determine an appropriate dose for their specific needs.

FAQs

Is liposomal Urolithin A safe?

Yes, clinical trials indicate that Urolithin A is generally well-tolerated with a good safety profile, reporting only mild and non-serious adverse events.

How soon can I expect to see benefits from Urolithin A?

Some mitochondrial and anti-inflammatory effects may appear within 4 weeks, while improvements in muscle strength might require longer periods of consistent supplementation.

Does Urolithin A help increase muscle mass?

Current evidence suggests Urolithin A improves muscle strength and endurance, but it has not been shown to significantly increase muscle mass or overall body anthropometrics.

Is Urolithin A effective for cognitive health?

Preclinical studies show promising neuroprotective effects, but human clinical trials are still needed to confirm its efficacy for cognitive health in humans.

Does the liposomal form of Urolithin A offer better efficacy?

Liposomal delivery is designed to enhance absorption and bioavailability, which likely improves its efficacy, but direct head-to-head clinical comparisons are limited.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/39002645/ – This systematic review of 5 randomized controlled trials (RCTs) involving 250 healthy individuals found that Urolithin A (10-1000 mg/day for 28 days to 4 months) demonstrated dose-dependent anti-inflammatory effects, upregulated mitochondrial and autophagy markers, and improved muscle strength/endurance. It noted no effects on mitochondrial ATP production or cardiovascular outcomes and reported only mild/moderate unrelated adverse events. The review highlighted the short duration of studies and limited physiological systems examined as limitations.
https://openmedicinalchemistryjournal.com/VOLUME/19/ELOCATOR/e18741045375825/PDF/ – This comprehensive review summarizes the molecular mechanisms of Urolithin A, including its activation of SIRT1/mTOR pathways, promotion of mitochondrial biogenesis, anti-inflammatory effects, and improvements in metabolic parameters. It references RCTs demonstrating enhanced insulin sensitivity and mitochondrial function in pre-diabetic individuals and discusses neuroprotective effects observed in Alzheimer's disease models. The review provides a strong overview of UA's diverse health benefits and underlying mechanisms.
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Urolithin_A_UPDATE_(supplement).pdf – This report summarizes preclinical randomized controlled trials in Alzheimer's mouse models, indicating that Urolithin A treatment reduced amyloid-beta deposition, decreased neuroinflammation, and improved cognitive performance. It delves into mechanistic insights, particularly UA's role in enhancing mitophagy and lysosomal function. The report emphasizes the promising nature of these findings and calls for human clinical trials to validate the efficacy of Urolithin A for cognitive health.